EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3 ‐Mutated AML : A FILO ‐ DATAML ‐ PETHEMA Real‐World Study

Gaspar Aspas Requena iD, Pau Montesinos iD, Emilie Bérard iD, Sarah Bertoli iD, Rebeca Rodríguez-Veiga iD, Celestine Simand, Laura Torres iD, Pierre Peterlin iD, Mar Tormo iD, Rudy Birsen iD, Juan Miguel Bergua-Burgues iD, Emmanuelle Tavernier iD und 20 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70233 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Gaspar Aspas Requena und 31 weiteren Autor:innen. Beteiligte Einrichtung: Montpellier University Hospital, Service d'Hématologie Clinique, Montpellier, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3 ‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC ( n = 194) versus IC alone ( n = 371) in 565 patients with FLT3 ‐mutated AML aged ≥ 60 years (median age 67.5 years; 35.6% ≥ 70 years). MIDO+IC was associated with lower day‐60 early death (8.2% vs. 21.4%, p < 0.0001) and higher composite complete remission (CRc) rates (78.9% vs. 63.1%, p < 0.0001). After a median follow‐up of 46.0 months, median overall survival (OS) was 24.2 months for MIDO+IC versus 8.7 months for IC ( p < 0.0001), with 5‐year OS rates of 40.6% vs. 12.9%, respectively. Event‐free survival (EFS; median 13.5 vs. 4.6 months; 5‐year EFS: 36.0% vs. 10.1%) and relapse‐free survival (RFS; median 20.2 vs. 8.0 months; 5‐year RFS: 45.4% vs. 15.7%) were also significantly improved (both p < 0.0001). The 5‐year cumulative incidence of relapse was lower with MIDO+IC (47.8% vs. 67.1%, p < 0.001). In multivariate analyses, midostaurin was an independent favorable prognostic factor for CRc (aOR 1.97 [95% CI: 1.29–2.98]), OS (aHR 0.46 [95% CI: 0.36–0.58]), EFS (aHR 0.49 [95% CI: 0.39–0.60]), and RFS (aHR 0.47 [CI: 0.36–0.62]) (all p ≤ 0.002). These benefits were confirmed by propensity score matching. This large real‐world study demonstrates that combining midostaurin with IC significantly improves remission rates and survival outcomes in elderly patients with FLT3 ‐mutated AML, supporting its consideration in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationStaurosporineAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease-Free SurvivalRegistriesRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

FLT3‐mutated AMLelderly patientsintensive chemotherapymidostaurinreal‐world data

Substanzen

FLT3 protein, humanfms-Like Tyrosine Kinase 3midostaurinStaurosporine

Autor:innen und Institutionen

  • Montpellier University Hospital, Service d'Hématologie Clinique, Montpellier, France.
  • University of Montpellier, Montpellier, France.
  • Hospital Universitario y Politécnico La Fe, Servicio de Hematología, Valencia, Spain.
  • Department of Clinical Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France.
  • CERPOP, Inserm, University Toulouse III Paul Sabatier, Toulouse, France.
  • Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'Hématologie, Université de Toulouse, Toulouse, France.

ORCID-Profile: Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, Sarah Bertoli, Rebeca Rodríguez-Veiga, Laura Torres, Pierre Peterlin, Mar Tormo, Rudy Birsen, Juan Miguel Bergua-Burgues, Emmanuelle Tavernier, Martin Carré, Eduardo Rodríguez-Arbolí, Corentin Orvain, Carlos Rodríguez-Medina, Lauren Veronese, Maria Jose Sayas Lloris, Eric Delabesse, Ariane Mineur, María García-Fortes, Romain Guieze, Lorenzo Algarra Algarra, Christian Recher, Pierre-Yves Dumas, David Martínez-Cuadrón

Zitieren

APA

Aspas Requena, G., Montesinos, P., Bérard, E., Bertoli, S., Rodríguez-Veiga, R., Simand, C., Torres, L., Peterlin, P., Tormo, M., Birsen, R., Bergua-Burgues, J. M., Tavernier, E., Bernal Del Castillo, T., Carré, M., Gil, C., Contejean, A., Rodríguez-Arbolí, E., Orvain, C., Rodríguez-Medina, C., …, & Martínez-Cuadrón, D. (2026). Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3 ‐Mutated AML : A FILO ‐ DATAML ‐ PETHEMA Real‐World Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70233

Vancouver

Aspas Requena G, Montesinos P, Bérard E, Bertoli S, Rodríguez-Veiga R, Simand C, et al. Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3 ‐Mutated AML : A FILO ‐ DATAML ‐ PETHEMA Real‐World Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70233

BibTeX
@article{AspasRequena2026,
  author = {Aspas Requena, Gaspar and Montesinos, Pau and Bérard, Emilie and Bertoli, Sarah and Rodríguez-Veiga, Rebeca and Simand, Celestine and Torres, Laura and Peterlin, Pierre and Tormo, Mar and Birsen, Rudy and Bergua-Burgues, Juan Miguel and Tavernier, Emmanuelle and Bernal Del Castillo, Teresa and Carré, Martin and Gil, Cristina and Contejean, Adrien and Rodríguez-Arbolí, Eduardo and Orvain, Corentin and Rodríguez-Medina, Carlos and Veronese, Lauren and Sayas Lloris, Maria Jose and Delabesse, Eric and Serrano, Josefina and Mineur, Ariane and García-Fortes, María and Guieze, Romain and Amigo, Maria Luz and Pigneux, Arnaud and Algarra Algarra, Lorenzo and Recher, Christian and Dumas, Pierre-Yves and Martínez-Cuadrón, David},
  title = {Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3 ‐Mutated AML : A FILO ‐ DATAML ‐ PETHEMA Real‐World Study},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70233}
}
Kostenlos starten →